Markus Warmuth Biography and Net Worth

Markus brings over 20 years of experience in drug discovery and precision medicine to Monte Rosa Therapeutics. He joined Monte Rosa Therapeutics from Third Rock Ventures, where he worked as an Entrepreneur-in-Residence and played an integral role in the venture capital firm’s formation of new biotech companies. Prior to his role at Third Rock Ventures, Markus spent seven years as the Chief Executive Officer of H3 Biomedicine, a biopharmaceutical company that specialized in the discovery and development of genomics-based precision oncology treatments. Markus has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as Executive Director and Cambridge Site Head for Oncology Discovery. While at Novartis, he and his teams were involved in the development of Ceritinib and Ribociclib, as well as the discovery of the allosteric Abl inhibitor Asciminib, amongst others. He also currently serves as a Venture Partner at Versant Ventures and is a Member of the Board of Directors of Ventus Therapeutics. He earned his M.D. from Ludwig Maximilian University, in Munich, Germany, and currently resides in Boston, MA.